Emphysema Treatment Market by Treatment Type (Pharmacological, Surgical), Drug Class (Anticholinergics, Beta-Agonists, Combination Drugs), Therapy Line, Route Of Administration, Dosage Form, Product Type, Distribution Channel - Global Forecast 2025-2032
Description
The Emphysema Treatment Market was valued at USD 6.83 billion in 2024 and is projected to grow to USD 7.32 billion in 2025, with a CAGR of 7.22%, reaching USD 11.94 billion by 2032.
Concise contextual framing of current emphysema treatment realities highlighting therapeutic diversity clinical priorities and health system delivery challenges
Emphysema remains a complex chronic respiratory condition that demands integrated clinical and commercial responses. This introduction frames the contemporary landscape by situating patient needs, therapeutic modalities, and healthcare system pressures within a coherent narrative that highlights both clinical innovation and practical delivery challenges.
The burden of care is being reshaped by advances in pharmacological regimens alongside refinements in surgical approaches, each driven by evolving evidence, device engineering, and patient preference. As clinicians and payers prioritize outcomes that improve functional status and reduce exacerbations, stakeholders must reconcile efficacy with tolerability and real-world adherence. Throughout this document, emphasis is placed on bridging the translational gap between clinical trial findings and routine care pathways, while recognizing that payers and providers increasingly demand demonstrable value and scalable models of delivery.
Assessment of converging clinical innovations regulatory trends and digital care pathways reshaping patient-centered emphysema management dynamics
The emphysema landscape is undergoing transformative shifts driven by complementary advances in therapeutics, delivery technologies, and health system expectations. Pharmacological innovation is moving beyond incremental improvements to emphasize combination formulations and inhalation technologies that enhance lung deposition and patient adherence. Concurrently, surgical and device-based options are benefiting from more precise patient selection criteria, improved perioperative protocols, and less invasive techniques that lower morbidity and expand candidacy among moderate-to-severe patients.
Regulatory and reimbursement paradigms are shifting in parallel, with value-based contracting and outcomes-linked agreements increasingly shaping commercialization strategies. Digital health and remote monitoring tools are entering routine pathways, enabling clinicians to detect deterioration earlier and tailor therapy dynamically. Taken together, these shifts are converging to produce a more patient-centric, outcomes-driven environment where multidisciplinary care, shared decision-making, and longitudinal data capture define successful interventions.
Evaluation of how recent United States tariff policies are altering supply chain decisions pricing strategies and stakeholder collaboration across emphysema care
Recent tariff policies in the United States have introduced new frictions into supply chains for medical devices, inhalation platforms, and certain active pharmaceutical ingredients. These trade measures have catalyzed re-evaluation of procurement strategies across manufacturers, distributors, and provider systems, prompting a reassessment of regional sourcing, inventory buffers, and contractual terms with suppliers. In practice, organizations are responding by diversifying manufacturing footprints, negotiating longer-term supply agreements, and accelerating localization of critical components where feasible.
Beyond immediate cost considerations, the tariffs have influenced strategic planning for product launches and device rollouts. Manufacturers are carefully modelling the implications for device pricing and reimbursement dialogues, while health systems are prioritizing cost containment without compromising access to clinically indicated therapies. Over time, these shifts may encourage closer collaboration between manufacturers and payers to align on total-cost-of-care frameworks and to design programs that mitigate short-term price volatility while sustaining long-term investment in innovation.
Integrated segmentation perspectives mapping treatment types drug classes therapy lines administration routes dosage forms distribution channels and product type for strategic prioritization
A nuanced understanding of segmentation clarifies therapeutic pathways and market dynamics by mapping treatments to clinical need and delivery modality. When treatments are classified by treatment type, pharmacological options encompass antibiotics, bronchodilators, corticosteroids, and mucolytics, and surgical alternatives include bullectomy, lung transplantation, lung volume reduction surgery, and valve therapy; appreciating this distinction helps align clinical trial design, patient selection, and reimbursement narratives. Drug class segmentation further separates agents into anticholinergics, beta-agonists, and combination therapies, which informs formulary placement and comparative effectiveness assessments as clinicians weigh monotherapy against combination regimens.
Therapy line segmentation-adjunctive, first-line, maintenance, and rescue-offers a timeline for therapeutic intervention and clarifies expected outcomes and metrics for each phase; within maintenance strategies, combination therapies, long-acting anticholinergics, and long-acting beta-agonists play distinct roles in sustaining lung function and preventing exacerbations, while rescue treatments rely on short-acting anticholinergics and short-acting beta-agonists to manage acute symptoms. Route of administration is another critical axis: inhalation methods include dry powder inhalers, metered dose inhalers, nebulizers, and soft mist inhalers; intravenous administration can be delivered via infusion or injection; and oral routes encompass capsules, solutions, and tablets. Each route carries implications for adherence, patient training, and device support services. Dosage form and distribution channel intersect with these considerations: capsules, inhalers, nebulizers, solutions, and tablets represent the primary dosage formats, and distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, affecting both access and point-of-care logistics. Finally, product type differentiates between branded and generic offerings, which has direct consequences for pricing dynamics, prescriber preference, and lifecycle management. Synthesizing these segmentation lenses enables stakeholders to prioritize investment in formulations and delivery systems that meet clinical needs while fitting into prevailing procurement and care-delivery models.
Comparative regional analysis of regulatory environments healthcare infrastructure and adoption pathways shaping emphysema treatment access across major global regions
Regional dynamics shape how emphysema treatments are developed, accessed, and deployed, influenced by regulatory regimes, healthcare infrastructure, and patient demographics. In the Americas, healthcare systems vary from public to predominantly private financing structures, which affects reimbursement strategies and adoption cycles for novel devices and pharmacotherapies. Clinical practice patterns emphasize outpatient management and multidisciplinary care, and distribution channels such as hospital and retail pharmacies play pivotal roles in ensuring continuity of therapy.
In Europe, Middle East & Africa, heterogeneity across national health authorities and payer models requires adaptive launch plans and localized evidence generation to secure favorable placement. Regulatory timelines and HTA requirements in parts of Europe necessitate robust comparative effectiveness data and real-world evidence to support reimbursement. The Middle East and Africa present both challenges and opportunities; constrained resources in some markets increase emphasis on cost-effective generics and simplified delivery mechanisms, while wealthier markets show demand for advanced surgical and device-based interventions. In the Asia-Pacific region, rapid uptake of inhalation technologies and an expanding respiratory specialty network drive innovation adoption, but diverse regulatory regimes and local manufacturing capacities influence supply strategies. Across these regions, manufacturers and providers must calibrate market access approaches, tailoring clinical engagement, pricing constructs, and distribution partnerships to regional nuances while leveraging global evidence to build consistent clinical narratives.
Competitive and collaborative company dynamics emphasizing product differentiation integrated solutions clinical partnerships and center-of-excellence models in emphysema care
Competitive dynamics are being driven by established pharmaceutical companies, specialized device manufacturers, and surgical centers of excellence, each contributing distinct capabilities to the emphysema care continuum. Product differentiation increasingly rests on formulation science, device ergonomics, and supporting services such as patient training, adherence programs, and remote monitoring. Strategic partnerships between drug developers and device firms are emerging to create integrated therapeutic solutions that pair optimized pharmacology with user-friendly delivery platforms, thereby enhancing both clinical outcomes and patient experience.
In parallel, smaller innovators focusing on novel valve technologies and minimally invasive surgical techniques are influencing referral patterns and expanding treatment options for patients previously deemed unsuitable for surgery. Health systems and payers are responding by developing center-of-excellence models to concentrate expertise and improve outcomes, which in turn shapes referral networks and adoption timing. For market participants, differentiating through robust clinical evidence, streamlined supply chains, and comprehensive post-market support will be essential to secure clinician trust and long-term institutional partnerships.
Actionable strategic priorities for industry leaders to enhance product adoption supply resilience evidence generation and integrated care models for emphysema management
Industry leaders should focus on five strategic priorities to translate insights into competitive advantage and improved patient outcomes. First, prioritize development and launch plans that align device design with real-world usage by patients and clinicians, ensuring ease of use, clear instructions, and adherence supports are embedded from the outset. Second, adopt supply chain resilience measures such as diversified sourcing, strategic inventory planning, and close supplier collaboration to mitigate tariff-related and geopolitical disruptions while maintaining continuity of care. Third, invest in real-world evidence generation and health economic analyses to support engagement with payers and health technology assessment bodies, demonstrating value across clinical and economic endpoints.
Fourth, pursue partnerships that integrate pharmacological and device innovations, coupled with digital health tools that enable remote monitoring and proactive care management. Such integrated offerings can differentiate propositions and align with value-based reimbursement models. Finally, tailor market access strategies to regional requirements, building localized evidence packages and flexible pricing approaches that reflect payer expectations and healthcare delivery realities. By executing on these priorities, organizations can better position themselves to influence treatment pathways, secure favorable institutional relationships, and deliver measurable improvements in patient outcomes.
Transparent multisource research methodology combining clinical literature analysis expert clinician interviews and commercial signal assessment to derive actionable insights
The research approach underpinning this executive summary combined multi-source evidence synthesis, expert clinician interviews, and structured assessment of clinical and commercial trends. Peer-reviewed clinical literature, regulatory announcements, and specialty society guidelines were analyzed to map therapeutic standards of care and evolving recommendations. In addition, qualitative interviews with pulmonologists, thoracic surgeons, and hospital pharmacists provided real-world perspectives on treatment selection, device utilization, and barriers to adherence.
Commercial and policy signals were evaluated through a review of public filings, procurement practices, and payer guidance to identify changes in access and reimbursement that affect product adoption. Where possible, triangulation across these inputs was used to validate findings and to surface convergent themes. The methodology emphasized transparency and reproducibility by documenting source types and interview frameworks, and by applying clear inclusion criteria for clinical and policy materials to ensure that the resulting insights are both actionable and defensible.
Concise synthesis highlighting the imperative for integrated evidence driven approaches supply resilience and localized access strategies to advance emphysema care
In summary, the emphysema treatment domain is maturing into a more integrated and outcome-focused system where pharmacological advances, device innovation, and surgical refinements intersect with changing reimbursement models and supply chain realities. Stakeholders who align clinical evidence, delivery convenience, and payer-relevant value propositions will gain the greatest traction. Furthermore, regional nuances in regulation, infrastructure, and procurement require differentiated strategies that respect local realities while leveraging global clinical evidence.
The path forward requires coordinated action across product development, market access, and clinical engagement functions. By prioritizing patient-centered design, supply chain resilience, real-world evidence generation, and strategic partnerships, organizations can both improve clinical outcomes for patients with emphysema and create sustainable commercial models that support ongoing innovation.
Note: PDF & Excel + Online Access - 1 Year
Concise contextual framing of current emphysema treatment realities highlighting therapeutic diversity clinical priorities and health system delivery challenges
Emphysema remains a complex chronic respiratory condition that demands integrated clinical and commercial responses. This introduction frames the contemporary landscape by situating patient needs, therapeutic modalities, and healthcare system pressures within a coherent narrative that highlights both clinical innovation and practical delivery challenges.
The burden of care is being reshaped by advances in pharmacological regimens alongside refinements in surgical approaches, each driven by evolving evidence, device engineering, and patient preference. As clinicians and payers prioritize outcomes that improve functional status and reduce exacerbations, stakeholders must reconcile efficacy with tolerability and real-world adherence. Throughout this document, emphasis is placed on bridging the translational gap between clinical trial findings and routine care pathways, while recognizing that payers and providers increasingly demand demonstrable value and scalable models of delivery.
Assessment of converging clinical innovations regulatory trends and digital care pathways reshaping patient-centered emphysema management dynamics
The emphysema landscape is undergoing transformative shifts driven by complementary advances in therapeutics, delivery technologies, and health system expectations. Pharmacological innovation is moving beyond incremental improvements to emphasize combination formulations and inhalation technologies that enhance lung deposition and patient adherence. Concurrently, surgical and device-based options are benefiting from more precise patient selection criteria, improved perioperative protocols, and less invasive techniques that lower morbidity and expand candidacy among moderate-to-severe patients.
Regulatory and reimbursement paradigms are shifting in parallel, with value-based contracting and outcomes-linked agreements increasingly shaping commercialization strategies. Digital health and remote monitoring tools are entering routine pathways, enabling clinicians to detect deterioration earlier and tailor therapy dynamically. Taken together, these shifts are converging to produce a more patient-centric, outcomes-driven environment where multidisciplinary care, shared decision-making, and longitudinal data capture define successful interventions.
Evaluation of how recent United States tariff policies are altering supply chain decisions pricing strategies and stakeholder collaboration across emphysema care
Recent tariff policies in the United States have introduced new frictions into supply chains for medical devices, inhalation platforms, and certain active pharmaceutical ingredients. These trade measures have catalyzed re-evaluation of procurement strategies across manufacturers, distributors, and provider systems, prompting a reassessment of regional sourcing, inventory buffers, and contractual terms with suppliers. In practice, organizations are responding by diversifying manufacturing footprints, negotiating longer-term supply agreements, and accelerating localization of critical components where feasible.
Beyond immediate cost considerations, the tariffs have influenced strategic planning for product launches and device rollouts. Manufacturers are carefully modelling the implications for device pricing and reimbursement dialogues, while health systems are prioritizing cost containment without compromising access to clinically indicated therapies. Over time, these shifts may encourage closer collaboration between manufacturers and payers to align on total-cost-of-care frameworks and to design programs that mitigate short-term price volatility while sustaining long-term investment in innovation.
Integrated segmentation perspectives mapping treatment types drug classes therapy lines administration routes dosage forms distribution channels and product type for strategic prioritization
A nuanced understanding of segmentation clarifies therapeutic pathways and market dynamics by mapping treatments to clinical need and delivery modality. When treatments are classified by treatment type, pharmacological options encompass antibiotics, bronchodilators, corticosteroids, and mucolytics, and surgical alternatives include bullectomy, lung transplantation, lung volume reduction surgery, and valve therapy; appreciating this distinction helps align clinical trial design, patient selection, and reimbursement narratives. Drug class segmentation further separates agents into anticholinergics, beta-agonists, and combination therapies, which informs formulary placement and comparative effectiveness assessments as clinicians weigh monotherapy against combination regimens.
Therapy line segmentation-adjunctive, first-line, maintenance, and rescue-offers a timeline for therapeutic intervention and clarifies expected outcomes and metrics for each phase; within maintenance strategies, combination therapies, long-acting anticholinergics, and long-acting beta-agonists play distinct roles in sustaining lung function and preventing exacerbations, while rescue treatments rely on short-acting anticholinergics and short-acting beta-agonists to manage acute symptoms. Route of administration is another critical axis: inhalation methods include dry powder inhalers, metered dose inhalers, nebulizers, and soft mist inhalers; intravenous administration can be delivered via infusion or injection; and oral routes encompass capsules, solutions, and tablets. Each route carries implications for adherence, patient training, and device support services. Dosage form and distribution channel intersect with these considerations: capsules, inhalers, nebulizers, solutions, and tablets represent the primary dosage formats, and distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, affecting both access and point-of-care logistics. Finally, product type differentiates between branded and generic offerings, which has direct consequences for pricing dynamics, prescriber preference, and lifecycle management. Synthesizing these segmentation lenses enables stakeholders to prioritize investment in formulations and delivery systems that meet clinical needs while fitting into prevailing procurement and care-delivery models.
Comparative regional analysis of regulatory environments healthcare infrastructure and adoption pathways shaping emphysema treatment access across major global regions
Regional dynamics shape how emphysema treatments are developed, accessed, and deployed, influenced by regulatory regimes, healthcare infrastructure, and patient demographics. In the Americas, healthcare systems vary from public to predominantly private financing structures, which affects reimbursement strategies and adoption cycles for novel devices and pharmacotherapies. Clinical practice patterns emphasize outpatient management and multidisciplinary care, and distribution channels such as hospital and retail pharmacies play pivotal roles in ensuring continuity of therapy.
In Europe, Middle East & Africa, heterogeneity across national health authorities and payer models requires adaptive launch plans and localized evidence generation to secure favorable placement. Regulatory timelines and HTA requirements in parts of Europe necessitate robust comparative effectiveness data and real-world evidence to support reimbursement. The Middle East and Africa present both challenges and opportunities; constrained resources in some markets increase emphasis on cost-effective generics and simplified delivery mechanisms, while wealthier markets show demand for advanced surgical and device-based interventions. In the Asia-Pacific region, rapid uptake of inhalation technologies and an expanding respiratory specialty network drive innovation adoption, but diverse regulatory regimes and local manufacturing capacities influence supply strategies. Across these regions, manufacturers and providers must calibrate market access approaches, tailoring clinical engagement, pricing constructs, and distribution partnerships to regional nuances while leveraging global evidence to build consistent clinical narratives.
Competitive and collaborative company dynamics emphasizing product differentiation integrated solutions clinical partnerships and center-of-excellence models in emphysema care
Competitive dynamics are being driven by established pharmaceutical companies, specialized device manufacturers, and surgical centers of excellence, each contributing distinct capabilities to the emphysema care continuum. Product differentiation increasingly rests on formulation science, device ergonomics, and supporting services such as patient training, adherence programs, and remote monitoring. Strategic partnerships between drug developers and device firms are emerging to create integrated therapeutic solutions that pair optimized pharmacology with user-friendly delivery platforms, thereby enhancing both clinical outcomes and patient experience.
In parallel, smaller innovators focusing on novel valve technologies and minimally invasive surgical techniques are influencing referral patterns and expanding treatment options for patients previously deemed unsuitable for surgery. Health systems and payers are responding by developing center-of-excellence models to concentrate expertise and improve outcomes, which in turn shapes referral networks and adoption timing. For market participants, differentiating through robust clinical evidence, streamlined supply chains, and comprehensive post-market support will be essential to secure clinician trust and long-term institutional partnerships.
Actionable strategic priorities for industry leaders to enhance product adoption supply resilience evidence generation and integrated care models for emphysema management
Industry leaders should focus on five strategic priorities to translate insights into competitive advantage and improved patient outcomes. First, prioritize development and launch plans that align device design with real-world usage by patients and clinicians, ensuring ease of use, clear instructions, and adherence supports are embedded from the outset. Second, adopt supply chain resilience measures such as diversified sourcing, strategic inventory planning, and close supplier collaboration to mitigate tariff-related and geopolitical disruptions while maintaining continuity of care. Third, invest in real-world evidence generation and health economic analyses to support engagement with payers and health technology assessment bodies, demonstrating value across clinical and economic endpoints.
Fourth, pursue partnerships that integrate pharmacological and device innovations, coupled with digital health tools that enable remote monitoring and proactive care management. Such integrated offerings can differentiate propositions and align with value-based reimbursement models. Finally, tailor market access strategies to regional requirements, building localized evidence packages and flexible pricing approaches that reflect payer expectations and healthcare delivery realities. By executing on these priorities, organizations can better position themselves to influence treatment pathways, secure favorable institutional relationships, and deliver measurable improvements in patient outcomes.
Transparent multisource research methodology combining clinical literature analysis expert clinician interviews and commercial signal assessment to derive actionable insights
The research approach underpinning this executive summary combined multi-source evidence synthesis, expert clinician interviews, and structured assessment of clinical and commercial trends. Peer-reviewed clinical literature, regulatory announcements, and specialty society guidelines were analyzed to map therapeutic standards of care and evolving recommendations. In addition, qualitative interviews with pulmonologists, thoracic surgeons, and hospital pharmacists provided real-world perspectives on treatment selection, device utilization, and barriers to adherence.
Commercial and policy signals were evaluated through a review of public filings, procurement practices, and payer guidance to identify changes in access and reimbursement that affect product adoption. Where possible, triangulation across these inputs was used to validate findings and to surface convergent themes. The methodology emphasized transparency and reproducibility by documenting source types and interview frameworks, and by applying clear inclusion criteria for clinical and policy materials to ensure that the resulting insights are both actionable and defensible.
Concise synthesis highlighting the imperative for integrated evidence driven approaches supply resilience and localized access strategies to advance emphysema care
In summary, the emphysema treatment domain is maturing into a more integrated and outcome-focused system where pharmacological advances, device innovation, and surgical refinements intersect with changing reimbursement models and supply chain realities. Stakeholders who align clinical evidence, delivery convenience, and payer-relevant value propositions will gain the greatest traction. Furthermore, regional nuances in regulation, infrastructure, and procurement require differentiated strategies that respect local realities while leveraging global clinical evidence.
The path forward requires coordinated action across product development, market access, and clinical engagement functions. By prioritizing patient-centered design, supply chain resilience, real-world evidence generation, and strategic partnerships, organizations can both improve clinical outcomes for patients with emphysema and create sustainable commercial models that support ongoing innovation.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of personalized inhalation devices with smart monitoring capabilities for emphysema patients
- 5.2. Adoption of regenerative stem cell therapies targeting alveolar tissue repair in emphysema management
- 5.3. Market adoption of next generation long acting bronchodilator combinations with enhanced safety profiles
- 5.4. Integration of cloud connected spirometry and digital health platforms for remote emphysema monitoring
- 5.5. Development of targeted anti inflammatory biologics to mitigate chronic alveolar degradation in emphysema
- 5.6. Collaborations between biotech startups and pulmonary research centers to expedite emphysema drug approvals
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Emphysema Treatment Market, by Treatment Type
- 8.1. Pharmacological
- 8.1.1. Antibiotics
- 8.1.2. Bronchodilators
- 8.1.3. Corticosteroids
- 8.1.4. Mucolytics
- 8.2. Surgical
- 8.2.1. Bullectomy
- 8.2.2. Lung Transplantation
- 8.2.3. Lung Volume Reduction Surgery
- 8.2.4. Valve Therapy
- 9. Emphysema Treatment Market, by Drug Class
- 9.1. Anticholinergics
- 9.2. Beta-Agonists
- 9.3. Combination Drugs
- 10. Emphysema Treatment Market, by Therapy Line
- 10.1. Adjunctive
- 10.2. First-Line
- 10.3. Maintenance
- 10.3.1. Combination Therapy
- 10.3.2. Long-Acting Anticholinergics
- 10.3.3. Long-Acting Beta-Agonists
- 10.4. Rescue
- 10.4.1. Short-Acting Anticholinergics
- 10.4.2. Short-Acting Beta-Agonists
- 11. Emphysema Treatment Market, by Route Of Administration
- 11.1. Inhalation
- 11.1.1. Dry Powder Inhaler
- 11.1.2. Metered Dose Inhaler
- 11.1.3. Nebulizer
- 11.1.4. Soft Mist Inhaler
- 11.2. Intravenous
- 11.2.1. Infusion
- 11.2.2. Injection
- 11.3. Oral
- 11.3.1. Capsule
- 11.3.2. Solution
- 11.3.3. Tablet
- 12. Emphysema Treatment Market, by Dosage Form
- 12.1. Capsule
- 12.2. Inhaler
- 12.3. Nebulizer
- 12.4. Solution
- 12.5. Tablet
- 13. Emphysema Treatment Market, by Product Type
- 13.1. Brand
- 13.2. Generic
- 14. Emphysema Treatment Market, by Distribution Channel
- 14.1. Hospital Pharmacy
- 14.2. Online Pharmacy
- 14.3. Retail Pharmacy
- 15. Emphysema Treatment Market, by Region
- 15.1. Americas
- 15.1.1. North America
- 15.1.2. Latin America
- 15.2. Europe, Middle East & Africa
- 15.2.1. Europe
- 15.2.2. Middle East
- 15.2.3. Africa
- 15.3. Asia-Pacific
- 16. Emphysema Treatment Market, by Group
- 16.1. ASEAN
- 16.2. GCC
- 16.3. European Union
- 16.4. BRICS
- 16.5. G7
- 16.6. NATO
- 17. Emphysema Treatment Market, by Country
- 17.1. United States
- 17.2. Canada
- 17.3. Mexico
- 17.4. Brazil
- 17.5. United Kingdom
- 17.6. Germany
- 17.7. France
- 17.8. Russia
- 17.9. Italy
- 17.10. Spain
- 17.11. China
- 17.12. India
- 17.13. Japan
- 17.14. Australia
- 17.15. South Korea
- 18. Competitive Landscape
- 18.1. Market Share Analysis, 2024
- 18.2. FPNV Positioning Matrix, 2024
- 18.3. Competitive Analysis
- 18.3.1. GlaxoSmithKline plc
- 18.3.2. Boehringer Ingelheim International GmbH
- 18.3.3. AstraZeneca plc
- 18.3.4. Novartis AG
- 18.3.5. Teva Pharmaceutical Industries Ltd
- 18.3.6. Viatris Inc.
- 18.3.7. Chiesi Farmaceutici S.p.A.
- 18.3.8. Sunovion Pharmaceuticals Inc.
- 18.3.9. Sandoz International GmbH
- 18.3.10. Cipla Limited
- 18.3.11. Pfizer, Inc.
- 18.3.12. Roche Holding AG
- 18.3.13. Merck & Co., Inc.
- 18.3.14. Grifols S.A.
- 18.3.15. Verona Pharma plc
- 18.3.16. Pulmonx Corporation
- 18.3.17. ResMed, Inc.
- 18.3.18. Olympus Corporation
- 18.3.19. Baxter International Inc.
- 18.3.20. Boston Scientific Corporation
- 18.3.21. Amgen Inc.
- 18.3.22. Sanofi S.A.
- 18.3.23. Astellas Pharma Inc.
- 18.3.24. Mylan N.V.
- 18.3.25. Johnson & Johnson Services, Inc.
- 18.3.26. Theravance Biopharma, Inc.
- 18.3.27. Orion Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
